CD274 and neoplasm: In patients with PD-L1 expression of 1% or higher in tumor cells nivolumab and ipilimumab led to a better median OS compared with chemotherapy (18.0 months vs. 13.3 months; HR 0.69; CI 95% 0.55–0.87), whereas in the PD-L1 negative subgroup no difference was noted between both treatment arms.